Tolerance studies with brotizolam in hospitalized patients.
A long-term study of brotizolam (minimum 4 weeks: maximum 26 weeks) was carried out in hospitalized patients (29 to 95 years) who complained of sleep disturbance. 3.0% of the patients used 0.125 mg, 86.4% used 0.25 mg, and 10.0% used 0.5 mg daily. During the trial there was no evidence of tolerance. There were no symptoms of overdosage, physical and psychological dependency or withdrawal, and there were no interactions with the concurrently prescribed drugs. There were no changes in vital functions, haematology, or in the biochemical investigations of blood or urine which could be attributed to the drug.
D000328:Adult; D000368:Aged; D001381:Azepines / Q000627:therapeutic use* / Q000633:toxicity; D002986:Clinical Trials as Topic; D004361:Drug Tolerance; D005260:Female; D006760:Hospitalization; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use* / Q000633:toxicity; D008297:Male; D008875:Middle Aged; D012893:Sleep Wake Disorders / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome; D013997:Time Factors
D001381:Azepines; D006993:Hypnotics and Sedatives; C020960:brotizolam